AI Article Synopsis
- Robotic-assisted retroperitoneal lymph node dissection (R-RPLND) is a promising surgical technique for testicular cancer, offering lower morbidity than traditional open RPLND.
- R-RPLND is successfully being used for low-volume clinical stage II testicular cancer, in addition to its initial application for stage I, and has shown benefits like shorter hospital stays and less blood loss with similar complication rates.
- Future studies are needed to evaluate long-term outcomes and further strengthen the role of R-RPLND in treating testicular cancer.
Article Abstract
Purpose Of Review: Robotic-assisted retroperitoneal lymph node dissection (R-RPLND) is an emerging surgical option for testicular cancer with less morbidity than open RPLND. We outline the operative technique used at our center and review contemporary evidence in the advancement of R-RPLND.
Recent Findings: R-RPLND is being applied effectively beyond clinical stage I testicular cancer to treat low-volume, clinical stage II disease in both the primary and postchemotherapy setting. Compared with the open approach, R-RPLND offers shorter hospitalization and less blood loss with comparably low complications and oncologic control.
Summary: With ongoing adoption and optimization of R-RPLND, future studies will assess long-term oncologic outcomes and disseminate R-RPLND in the treatment of testicular cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MOU.0000000000001094 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!